Credit Suisse’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Credit Suisse’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-140,493	Closed	-$355K	–	3073
2023 Q4	$355K	Buy	140,493 +36,170	+35%	+$84.2K	﹤0.01%	2876
2023 Q3	$249K	Sell	104,323 -8,534	-8%	-$18.9K	﹤0.01%	2984
2023 Q2	$261K	Buy	112,857 +8,291	+8%	+$23.4K	﹤0.01%	3040
2023 Q1	$267K	Buy	104,566 +11,338	+12%	+$32.5K	﹤0.01%	3036
2022 Q4	$234K	Buy	93,228 +157	+0.2%	+$438	﹤0.01%	3134
2022 Q3	$270K	Buy	93,071 +788	+0.9%	+$3.32K	﹤0.01%	3124
2022 Q2	$418K	Buy	92,283 +74,436	+417%	+$443K	﹤0.01%	2955
2022 Q1	$143K	Buy	+17,847	New	+$157K	﹤0.01%	3447

Credit Suisse's SLGC Position: Q1 2024 in Review

Credit Suisse sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 140,493 shares — an estimated $355K sold.

Credit Suisse first reported a position in SLGC in Q1 2022 and held it in 8 quarters. The position peaked at $418K in Q2 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

Credit Suisse reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
Credit Suisse sold 140,493 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $355K.
Credit Suisse first reported a position in SomaLogic, Inc. Class A Common Stock in Q1 2022 and held it in 8 quarters.
Credit Suisse's SomaLogic, Inc. Class A Common Stock position peaked at $418K in Q2 2022.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.